Muscarinic Acetylcholine Receptor M2 (CHRM2) - Pipeline Review, H1 2017 - 6 Companies & Drug Profiles - Research and Markets

DUBLIN--()--Research and Markets has announced the addition of the "Muscarinic Acetylcholine Receptor M2 (CHRM2) - Pipeline Review, H1 2017" report to their offering.

'Muscarinic Acetylcholine Receptor M2 (CHRM2) - Pipeline Review, H1 2017' outlays comprehensive information on the Muscarinic Acetylcholine Receptor M2 (CHRM2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Muscarinic Acetylcholine Receptor M2 (CHRM2) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 4, 2 and 2 respectively.

Report covers products from therapy areas Central Nervous System, Genito Urinary System And Sex Hormones, Cardiovascular, Dermatology and Genetic Disorders which include indications Alzheimer's Disease, Overactive Bladder, Depression, Parkinson's Disease, Amnesia, Amyotrophic Lateral Sclerosis, Anxiety Disorders, Axillary Hyperhidrosis, Cognitive Disorders, Epilepsy, Fragile X Syndrome, Infantile Spasm (West Syndrome), Movement Disorders, Multiple Sclerosis, Rett Syndrome, Schizophrenia, Stroke and Urinary Incontinence.

Key Topics Covered:

  1. Introduction
  2. Muscarinic Acetylcholine Receptor M2 (CHRM2) - Overview
  3. Muscarinic Acetylcholine Receptor M2 (CHRM2) - Therapeutics Development
  4. Products under Development by Stage of Development
  5. Products under Development by Therapy Area
  6. Products under Development by Indication
  7. Products under Development by Companies
  8. Muscarinic Acetylcholine Receptor M2 (CHRM2) - Therapeutics Assessment
  9. Assessment by Mechanism of Action
  10. Assessment by Route of Administration
  11. Assessment by Molecule Type
  12. Muscarinic Acetylcholine Receptor M2 (CHRM2) - Companies Involved in Therapeutics Development
  • Allergan Plc
  • Anavex Life Sciences Corp
  • FemmePharma Global Healthcare Inc
  • Juniper Pharmaceuticals Inc
  • Karuna Pharmaceuticals Inc
  • TheraVida Inc

For more information about this report visit https://www.researchandmarkets.com/research/6rv47p/muscarinic

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T. Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Central Nervous System Drugs

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T. Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Central Nervous System Drugs